#United States #New York #Pomerantz LLP #stock claims #Galectin Therapeutics

Pomerantz Law Firm Investigates Claims on Behalf of Galectin Therapeutics Investors

In a significant development for investors, the Pomerantz Law Firm has initiated an investigation into Galectin Therapeutics Inc. (NASDAQ: GALT), aiming to uncover potential securities fraud or other unlawful business practices involving the company and its leadership. The investigation arises following a troubling announcement regarding the firm’s product development and the FDA's response to their inquiry.

The Context of the Investigation

On December 19, 2025, Galectin released a statement that indicated the U.S. Food and Drug Administration (FDA) had provided feedback on the company's request to convene a Type C meeting concerning their investigational treatment, belapectin, designed to inhibit galectin-3. Though the FDA acknowledged the request, it opted for a written response instead of a meeting—a decision implying that there may be unresolved issues pertinent to the clinical trial’s design.

This lack of face-to-face clarification left many in the investment community uneasy, especially since the company noted ongoing alignment with the FDA on the proposed patient population. Still, the unresolved facets of the trial's design have raised questions, causing substantial concern among investors.

Following this press release, Galectin's stock took a considerable hit, plummeting by 28.9%, equivalent to a loss of $1.78 per share, which ultimately brought the closing price down to $4.38. This sharp decline has prompted further scrutiny into the company’s operational practices and disclosures.

Profile of Pomerantz Law Firm

Pomerantz LLP, renowned for its expertise in corporate, securities, and antitrust class litigation, has a historic reputation for advocating for victims of securities fraud and corporate misconduct. With offices spanning across major cities such as New York, London, and Tel Aviv, the firm is recognized as one of the leading entities in this legal sector. Founded by Abraham L. Pomerantz, a pioneer in securities class actions, the firm continues to uphold its legacy by vigorously pursuing justice for investors.

The firm invites any Galectin investors who feel they have been affected by the company's practices to get in touch with their legal team. By contacting Danielle Peyton directly at the firm, those with potential claims can gain insight into the potential for class action proceedings.

This investigation underscores the ongoing risks and challenges faced by investors in the biotech sector, where regulatory outcomes can dramatically influence market performance. As the situation unfolds, stakeholders should remain vigilant and informed about the developments surrounding Galectin Therapeutics and the implications for their investments.

How to Get Involved

Investors wishing to join the class action are encouraged to connect with Pomerantz LLP. This collaboration could potentially enable recovery for investors impacted by the stock's downturn resulting from recent disclosures.

For more information about this investigation or related topics, stakeholders should monitor updates from Pomerantz LLP or consult with legal experts specializing in securities litigation. As always, proactive engagement is paramount for investors navigating the complexities of the stock market and company disclosures.

• ---

In summary, as Pomerantz Law Firm embarks on this investigation, investors must stay informed about the developments affecting Galectin Therapeutics to protect their interests and ensure their rights are upheld in this challenging environment.